Active Pharmaceutical Ingredients (API) is estimated to be worth $388.0 billion by 2029
Added: (Fri Feb 03 2023)
Pressbox (Press Release) -
IQ4I Research & Consultancy published a new report on Active Pharmaceutical Ingredients (API) Global Market Forecast To 2029
The Active Pharmaceutical Ingredients (API) Global Market report covers five segments namely source, product, functionality, dosage form, and geography. These segments are further segmented as follows:
1. Global API Market based on Synthesis:
Synthetic API
Synthetic API based on customer base
o Branded API
o Generic API
Biotech API
Biotech API based on product type
o Antibodies
Monoclonal antibodies
Bi-Specific
Others
o Recombinant proteins
o Vaccines
o Cell Therapy
o Gene Therapy
o Others
Biotech API based on customer base
o Biologics
o Biosimilar
HPAPI
HPAPI based on customer base
o Branded API
o Generic API
2. Global API Market based on Business type:
Captive
o Branded Captive API
o Generic Captive API
Merchant
o Branded Merchant API
o Generic Merchant API
3. Global API Market based on Therapeutic Applications:
Infectious diseases
Oncology
Cardiovascular diseases
Central nervous system
Pulmonary diseases
Gastrointestinal diseases
Endocrine diseases
Metabolic disorders
Genitourinary diseases
Musculoskeletal diseases
Others
4. Global API Market, based on Region:
North America
Europe
Asia-Pacific
Rest of World
Each segment of this report offers market values for its sub-segments and geographies as well. It also provides market dynamics with respect to drivers, restraints, opportunities, and the performance of major key players.
As estimated by IQ4I Research, the API global market is expected to grow at a high single digit CAGR from 2022 to 2029 to reach $388,002.4 million by 2029. The major factors driving the API market are increasing incidence and prevalence of various chronic diseases, adoption of biologics in disease management & increasing regulatory approvals and increasing R&D expenditure & expansion of manufacturing facilities. Whereas, growing scope for HPAPI and next generation therapeutics such as cell therapy and gene therapy, increasing patent expiration and trend of outsourcing are providing immense opportunity to the API market. The high risk of contamination during the manufacturing of API, high cost for manufacturing of complex and advanced APIs, presence of alternatives and stringent regulations associated with pharma manufacturing are hindering the market growth.
The report covers business intelligence information of the Active Pharmaceutical Ingredients (API) global market segments based on synthesis, business type, application and geography. Revenue forecast and strategic analysis with respect to industry trends and contribution to the overall API market. Analysis of top-selling drugs and their average selling prices (ASP), Drug Master Filing (DMF), FDA approved manufacturing sites, patent and ANDA approvals, Global pharmaceutical API production and utilization volume of small molecule and biologics (In-house, contract manufacturing) and Product matrix. Identification of major market trends, factors driving, restraining, threatening and providing opportunities for the API market growth. Major players company profiles in the API Global market and analysis of their business strategies and market shares.
Major players in the Active pharmaceutical Ingredient (API) market are Catalent Inc (U.S.), Divis Laboratories (India), Lonza Group (Switzerland), Samsung Biologics, (South Korea), Wuxi Biologics (China), Wuxi Apptec (China), Pfizer Inc. (U.S.), EuroAPI (France), Thermo Fisher Scientific (Patheon N.V.) (U.S.) and Teva Pharmaceutical Industries Limited (Israel).